Regulatory Press Releases
PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY
Malmö, 18 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The preliminary results showed that PILA PHARMA's lead candidate, the TRPV1 antagonist, XEN-D0501, significantly reduced Abdominal Aorta Aneurysm growth in mice, establishing preclinical proof-of-concept. The hypothesis is…
PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO)
Malmö, 13 December 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the appointment of Hampus Darrell as new CFO. Hampus Darrell is joining with an extensive professional accounting tenure, and he will provide financial and accounting expertise to PILA PHARMA, thus securing a continuous high standard of financial management and reporting. He graduated from Lund University,…
PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN
Malmö, 14 November 2024 PILA PHARMA AB (publ) (FN STO:PILA) today announces the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical trial site for the conduct of PP-CT03 as well as the as having decided to seek further scientific advice as first step. On 17 October, PILA PHARMA informed of optimization changes to the…
PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
Malmö, 13 November 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group") to complete initial investigations on the effect of PILA PHARMA's lead molecule, XEN-D0501, on Abdominal Aorta Aneurism growth in mice. The hypothesis is that XEN-D0501 may…
PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN
Malmö, 17 October 2024 PILA PHARMA AB (publ) (FN STO:PILA) today announces it has chosen to alter the operational plan for its next clinical trial, PP-CT03, a phase 2a safety and tolerability trial in people living with obesity and type 2 diabetes. On 25 July, PILA PHARMA entered into agreement with a UK based clinical research organisation on supply of…